FDA Schedules September Public Hearing on Psychedelic Drug Therapies

The U.S. Food and Drug Administration (FDA) will hold a public hearing on September 14 to address key issues surrounding the use of psychedelic drugs in supervised therapeutic settings, according to a report from Jefferies. The virtual hearing is scheduled to run from 12:30 p.m. to 4:30 p.m. Eastern Time and will allow for public comment.

Hearing Agenda and Objectives

The hearing will be conducted by a presiding officer alongside panelists from the FDA's Center for Drug Evaluation and Research (CDER) and other federal partners. The agency has outlined several critical topics for discussion, signaling a structured approach to formalizing the regulatory pathway for these novel treatments.

Key areas on the agenda include:

• Provider training and credentialing requirements.
• Best practices for promoting patient safety.
• Considerations for ensuring equitable access to therapies.
• Standardization of data collection for clinical trials and real-world evidence.

Updated Regulatory Guidance

Ad

This public meeting follows the FDA's recent release of its final guidance on psychedelic drug development, which aims to help sponsors generate interpretable efficacy data and improve trial integrity. The updated 2026 guidance introduces a more flexible, risk-based approach to nonclinical studies compared to the 2023 draft.

Notably, the new framework reduces the reliance on traditional animal abuse-liability studies, allowing developers to instead use computational models based on a compound's chemical structure. It also lowers the threshold for using prior human experience in development, requiring "adequate" prior exposure rather than the previous, more stringent "extensive" exposure standard.

Market and Development Implications

The hearing and updated guidance underscore the FDA's commitment to advancing innovation in a field that has seen significant therapeutic interest. The agency noted it has already granted breakthrough therapy designations for several psychedelic compounds, including psilocybin, MDMA, LSD, and esketamine.

For investors and pharmaceutical companies, these developments provide greater clarity on the regulatory expectations for bringing psychedelic-assisted therapies to market. The structured dialogue and refined guidelines are critical steps in establishing the safety, efficacy, and quality standards required for potential drug approvals.